Shattuck Labs (NASDAQ:STTK – Get Free Report)‘s stock had its “hold” rating restated by analysts at Needham & Company LLC in a report issued on Thursday,Benzinga reports.
Other analysts have also issued reports about the company. Citigroup lowered Shattuck Labs from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $8.00 to $2.00 in a report on Wednesday, October 2nd. Evercore ISI raised shares of Shattuck Labs to a “strong-buy” rating in a research note on Wednesday, October 2nd. Finally, HC Wainwright cut shares of Shattuck Labs from a “buy” rating to a “neutral” rating in a research note on Tuesday, October 1st. Four research analysts have rated the stock with a hold rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $8.67.
Check Out Our Latest Report on STTK
Shattuck Labs Stock Performance
Insiders Place Their Bets
In related news, CEO Taylor Schreiber bought 36,500 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were acquired at an average price of $1.21 per share, for a total transaction of $44,165.00. Following the completion of the transaction, the chief executive officer now directly owns 71,002 shares in the company, valued at $85,912.42. This trade represents a 105.79 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 10.50% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC increased its stake in Shattuck Labs by 4.8% during the 1st quarter. SG Americas Securities LLC now owns 39,377 shares of the company’s stock worth $352,000 after buying an additional 1,788 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Shattuck Labs by 8.5% during the second quarter. Dimensional Fund Advisors LP now owns 69,062 shares of the company’s stock worth $266,000 after purchasing an additional 5,397 shares in the last quarter. American Century Companies Inc. raised its stake in Shattuck Labs by 25.4% in the 2nd quarter. American Century Companies Inc. now owns 47,367 shares of the company’s stock valued at $183,000 after purchasing an additional 9,608 shares during the last quarter. Atom Investors LP purchased a new position in Shattuck Labs in the 3rd quarter valued at $35,000. Finally, Readystate Asset Management LP purchased a new position in Shattuck Labs in the 3rd quarter valued at $39,000. Institutional investors and hedge funds own 58.74% of the company’s stock.
Shattuck Labs Company Profile
Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.
Featured Stories
- Five stocks we like better than Shattuck Labs
- Why is the Ex-Dividend Date Significant to Investors?
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- Election Stocks: How Elections Affect the Stock Market
- Top-Performing Non-Leveraged ETFs This Year
- What is the Australian Securities Exchange (ASX)
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.